News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
AtheroGenics Reports First Quarter 2006 Financial Results
April 20, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today reported financial results for the first quarter ended March 31, 2006.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Layoff Tracker
4DMT Thins Early-Stage Workforce, Focuses on Late-Stage Activities
July 3, 2025
·
152 min read
·
BioSpace Editorial Staff
Podcast
CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP
July 2, 2025
·
1 min read
·
Heather McKenzie
Collaboration
Argenx Makes $1.5B+ Play for UNP’s Macrocyclic Peptides Aimed at ‘Undruggable’ Targets
July 1, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
AbbVie Plunks Down $2.1B for Capstan and Its Novel CAR T Therapies
June 30, 2025
·
2 min read
·
Dan Samorodnitsky
